HIT Typ II in der operativen Medizin ... - Vascularcare.de

Weitere Magazine

Empfehlungen

Info

[74] Kodityal S, Manhas AH, Udden M, Rice L: Danaparoid for heparininducedthrombocytopenia: an analysis of treatment failures. Eur JHaematol 71 (2003) 109–13[75] Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F:Recom-binant hirudin as an alternative for anticoagulation duringcardiopulmonary bypass in patients with heparin-inducedthrombocytopenia type II: a 1-year experience in 57 patients.J Cardiothorac Vasc Anesth 14 (2000) 243–48[76] Koster A, Sanger S, Hansen R, Sodian R, Mertzlufft F, Harke C,Kuppe H, Hetzer R, Loebe M: Prevalence and persistence ofheparin/platelet factor 4 antibodies in patients with heparincoated and noncoated ventricular assist devices. ASAIO J 46(2000) 319–22[77] Koster A, Spiess B, Chew DP, Krabatsch T, Tambeur L, DeAnda A,Hetzer R, Kuppe H, Smedira NG, Lincoff AM: Effectiveness ofbivalirudin as a replacement for heparin during cardiopulmonarybypass in patients undergoing coronary artery bypass grafting.Am J Cardiol 93 (2004) 356-9[78] Kozek-Langenecker SA, Spiss CK, Gamsjager T, Domenig C,Zimpfer M: Anticoagulation with prostaglandins and unfractionatedheparin during continuous venovenous haemofiltration: a randomizedcontrolled trial. Wien Klin Wschr 114 (2002) 96–101[79] Kozek-Langenecker SA, Spiss CK, Michalek-Sauberer A, FelfernigM, Zimpfer M: Effect of prostacyclin on platelets, polymorphonuclearcells, and heterotypic cell aggregation during hemofiltration.Crit Care Med 31 (2003) 864–68[80] Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C,Gangl A: Citrate pharmacokinetics and metabolism in cirrhoticand noncirrhotic critically ill patients. Crit Care Med 31 (2003)2450–55[81] Lagrange F, Brun JL, Vergnes MC, Paolucci F, Nadal T, Leng JJ,Saux MC, Bannwarth B: Fondaparinux sodium does not cross theplacental barrier: study using the in-vitro human dually perfusedcotyledon model. Clin Pharmacokinet 41 Suppl 2 (2002) 47–49[82] Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A,Zimpfer M: Anticoagulation with prostacyclin and heparin duringcontinuous venovenous hemofiltration. Crit Care Med 22 (1994)1774–81[83] Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A,Zimpfer M: Anticoagulation with prostacyclin and heparinduring continuous venovenous hemofiltration. Crit Care Med 22(1994) 1774–81[84] Lebrazi J, Elalamy I, Samama MM: In vitro effect of melagatranand lepirudin on clot-bound thrombin. Thromb Res 110 (2003)249–52[85] Lefevre G, Duval M, Gauron S, Brookman LJ, Rolan PE, Morris TM,Piraino AJ, Morgan JM, Palmisano M, Close P: Effect of renalimpairment on the pharmacokinetics and pharmacodynamics ofdesirudin. Clin Pharmacol Ther 62 (1997) 50–59[86] Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban-915 Investigators: Argatroban anticoagulation in patients withheparin-induced thrombocytopenia. Arch Intern Med 163 (2003)1849–56[87] Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD,Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J 3rd, Parker HG, Kereiakes DJ, Harrington RA, Feit F,Maierson ES, Chew DP, Topol EJ; REPLACE-1 Investigators.Comparison of bivalirudin versus heparin during percutaneouscoronary intervention (the Randomized Evaluation of PCI LinkingAngiomax to Reduced Clinical Events [REPLACE]-1 trial).Am J Cardiol 93 (2004) 1092-6[88] Lindhoff-Last E, Bauersachs R: Heparin-induced thrombocytopenia-alternativeanticoagulation in pregnancy and lactation. SeminThromb Hemost 28 (2002) 439–46[89] Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdsen F,Wagner R, Ehrly AM, Bauersachs R: A prospective study on theincidence and clinical relevance of heparin-induced antibodies inpatients after vascular surgery. Thromb Res 15, 97 (2000) 387–93[90] Lisman T, Bijsterveld NR, Adelmeijer J, Meijers JC, Levi M,Nieuwenhuis HK, de Groot PG: Recombinant factor VIIa reversesthe in vitro and ex vivo anticoagulant and profibrinolytic effectsof fondaparinux. J Thromb Haemost 1 (2003) 2368–73[91] Lucas FV, Skrinska VA, Chisolm GM, Hesse BL: Stability of prostacyclinin human and rabbit whole blood and plasma. Thromb Res43 (1986) 379–87[92] Macchi L, Sarfati R, Guicheteau M: Thromboembolic prophylaxiswith danaparoid (Orgaran) in a high-thrombosis-risk pregnantwoman with a history of heparin-induced thrombocytopenia (HIT)and Widal's disease. Clin Appl Thromb Hemost 6 (2000) 187–89[93] Maetzke J, Hinrichs R, Staib G, Scharffetter-Kochanek K:Fondaparinux as a novel therapeutic alternative in a patient withheparin allergy. Allergy 59 (2004) 237–38[94] Magnani HN: Heparin-induced thrombocytopenia (HIT): an overviewof 230 patients treated with orgaran (Org 10172). ThrombHaemost 70 (1993) 554–61[95] Markwardt F, Fink G, Kaiser B: Pharmacological survey of recombinanthirudin. Pharmazie 43 (1988) 202–7[96] Markwardt F: Untersuchungen über den Mechanismus der blutgerinnungshemmendenWirkung des Hirudins. N.-S. Arch Pharmacol229 (1956) 389–99VASCULAR CARE 1/2005 VOL. 8 51
OriginalieCHRISTIAN VON HEYMANN, ORTRUD VARGAS HEIN, MARC KASTRUP, STANISLAO MORGERA, SABINE ZIEMER, CLAUDIA SPIES, CHARITÉ UNVERSITÄTSMEDIZIN BERLIN[97] Martin PY, Chevrolet JC, Suter P, Favre H: Anticoagulation inpatients treated by continuous venovenous hemofiltration: aretrospective study. Am J Kidney Dis 24 (1994) 806–12[98] Matthies B, Bürger T, Koch B, Böck M: Heparin-induzierteThrombozytopenie Typ II: Re-Exposition mit Heparin. Dtsch MedWschr 124 (1999) 1267–70[99] Mazoyer E, Drouet L, Delahousse B, Gruel Y, Rouyrre N: Activatedpartial thromboplastin time is more sensitive than ecarin clottingtime for monitoring low doses of desirudin. Thromb Res 106(2002) 271–72[100] Mehta R, McDonald B, Aguilar M, Ward D: Regional citrate anticoagulationfor continuous arteriovenous hemodialysis in critically illpatients. Kidney Int 38 (1990) 976–81[101] Merz S, Fehr R, Gulke C: Sinus vein thrombosis. A rare complicationof heparin-induced thrombocytopenia type II. Anaesthesist 53(2004) 551–54[102] Meuleman DG: Orgaran (Org 10172): its pharmacological profilein experimental models. Haemostasis 22 (2) (1992) 58–65[103] Meyer O, Salama A, Pittet N, Schwind P: Rapid detection of heparin-inducedantibodies with particle gel immunoassay (ID-HPF4).Lancet 354 (1999) 1525–26[104] Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, DamasP: Citrate vs. heparin for anticoagulation in continuous venovenoushemofiltration: a prospective randomized study. IntensiveCare Med 30 (2004) 260–65[105] Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D,Melzer C, Rosseau S, Zuckermann-Becker H, Neumayer HH:Metabolic Complications during Regional Citrate Anticoagulationin Continuous Venovenous Hemodialysis. Single CenterExperience. Nephron Clin Pract (in press)[106] Newman PM, Chong B: Heparin-induced thrombocytopenia: newevidence for the dynamic binding of purified anti-PF4-heparinantibodies to platelets and the resultant platelet activation. Blood96 (2000) 182–87[107] Ofosu FA: Anticoagulant mechanisms of Orgaran (Org 10172)and its fraction with high affinity to antithrombin III (Org 10849).Haemostasis 22 (2) (1992) 66–72[108] Olsson SB: Executive Steering Committee on behalf of theSPORTIF III Investigators. Stroke prevention with the oral directthrombin inhibitor ximelagatran compared with warfarin inpatients with non-valvular atrial fibrillation (SPORTIF III): randomisedcontrolled trial. Lancet 362 (2003) 1691–98[109] Palsson R, Niles JL: Regional citrate anticoagulation in continuousveno-venous hemofiltration in critically ill patients with a high riskof bleeding. Kidney Int 55 (1999) 1991–97[110] Peeters LLH, Hobbelen PMJ, Verkeste CM:Placental transfer ofOrg 10172, a low molecular weight heparinoid, in the awakelate-pregnant guinea pig. Thromb Res 44 (1986) 277–83[111] Potzsch B, Klovekorn WP, Madlener K: Use of heparin duringcardiopulmonary bypass in patients with a history of heparininducedthrombocytopenia. N Engl J Med 343 (2000) 515[112] Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G: Monitoring of rhirudin anticoagulation during cardiopulmonarybypass-assessment of the whole blood ecarin clottingtime. Thromb Haemost 77 (1997) 920–25[113] Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, AmiralJ, Gruel Y: Induction of monocyte tissue factor expression by antibodiesto heparin-platelet factor 4 complexes developed in heparin-inducedthrombocytopenia. Blood 97 (2001) 3300–302[114] Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokineticsand pharmacodynamics: effect of renal function, dose,and gender. Clin Pharmacol Therap 71 (2002) 433-439[115] Samama MM, Gerotziafas GT: Evaluation of the pharmacologicalproperties and clinical results of the synthetic pentasaccharide(fondaparinux). Thromb Res 109 (2003) 1–11[116] Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G,Gustafsson D: Inhibition of thrombin generation by the oral directthrombin inhibitor ximelagatran in shed blood from healthy malesubjects. Thromb Haemost 87 (2002) 300–305[117] Sarich TC, Wolzt M, Eriksson UG, Mattsson C, Schmidt A, Elg S,Anders-son M, Wollbratt M, Fager G, Gustafsson D: Effects ofximelagatran, an oral direct thrombin inhibitor, rhirudin and enoxaparinon thrombin generation and platelet activation in healthymale subjects. J Am Coll Cardiol 41 (4) (2003 Feb 19) 557–64[118] Schering Arzneimittelinformation: Tödlich verlaufene anaphylaktischeReaktionen mit Refludan (Lepirudin),(25.10.2002), unter:www.akdae.de/20/40/Archiv/2002/96_20021025.pdf[119] Schiffner R, Glaessl A, Landthaler M, Stolz W: Tolerance of desirudinin a patient with generalized eczema after intravenous challengewith heparin and a delayed-type skin reaction to high andlow molecular weight heparins and heparinoids. ContactDermatitis 42 (2000) 49[120] Schmahl KS, Ganjoo AK, Harloff MG: Orgaran (Org 10172) forcardiopulmonary bypass in heparin-induced thrombocytopenia:role of adjunctive plasmapheresis. J Cardiothorac Vasc Anesth10 (1996) 521–30[121] Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H:THRIVE III Investigators. Secondary prevention of venousthromboembolism with the oral direct thrombin inhibitor ximelagatran.N Engl J Med 349 (2003) 1713–2152VASCULAR CARE 1/2005 VOL. 8
Seite 4 und 5: Vielmehr sollte diese Option unter
Seite 6 und 7: In klinischen Untersuchungen unter
Seite 8 und 9: Auf Grund des thrombingenerierenden
Seite 10 und 11: Tabelle 4: Pharmakologisches Profil
Seite 12 und 13: Ein wichtiges Anwendungsgebiet von
Seite 14 und 15: Da Fondaparinux fast unverändert r
Seite 16 und 17: Melagatran/XimelagatranMelagatran u
Seite 18 und 19: Empfehlungen für denklinischen All
Seite 20 und 21: Werden HIT-II-Patienten unter laufe
Seite 22 und 23: Natrium-CitratNatrium-Citrat wird i
Seite 24 und 25: Abbildung: Antikoagulatorische Wirk
Seite 26 und 27: [24] De Vries JX, Schmitz-Kummer E,
Seite 30: [122] Sheridan D, Carter C, Kelton

HIT Typ II in der operativen Medizin ... - Vascularcare.de

Erfolgreiche ePaper selbst erstellen

Template löschen?

Als Template speichern?